Le Lézard
Classified in: Health, Covid-19 virus
Subject: AVO

AMA Prefers Death to Treating without Data, States the Association of American Physicians and Surgeons (AAPS)


TUCSON, Ariz., April 9, 2020 /PRNewswire/ -- American Medical Association president Patrice Harris, M.D., told CNN's Wolf Blitzer that she would not prescribe hydroxychloroquine and azithromycin to a patient with COVID-19. It would be "inappropriate prescribing" because the FDA has not approved the drug for this new virus. It might have negative side effects, including deaths. Also, we need to keep supplies available for patients who have lupus and other conditions she said. For COVID, "it is unproven.... At this point we just don't have the data."

In response, the Association of American Physicians and Surgeons (AAPS) released the following statement:

"Chloroquine (CQ) and hydroxychloroquine (HCQ) have been FDA approved for about 70 years and have been extensively and safely used worldwide for malaria and other conditions. Obtaining approval for a new indication is extremely costly and usually takes years. Although drugs cannot be marketed for an 'off-label' indication, they may be prescribed, and probably one in five prescriptions is off label.

"The Oath of Hippocrates states that physicians have the duty to 'prescribe according to my ability and my judgment.'

"So far, data are showing successful results, even in some patients who were near death. Results appear to be best when HCQ is given early in combination with zinc and the common antibiotic azithromycin. Data pouring in from many countries show that as many as 98 percent of patients improve with this treatment, and there is very little risk, according to our tabulation, which is being updated periodically.

"There are NO FDA-approved preventives or therapies for this novel illness. The ethical and humane action is for physicians to prescribe remedies for which there is a scientific basis and favorable current experience. These include HCQ as well as high-dose intravenous vitamin C. The alternative is to deny patients the best available chance to live.

"FDA bureaucracy has delayed testing and obstructed the provision of protective gear. Professional societies like the AMA, governors, and medical and pharmacy boards should not be forbidding the long-accepted practice of prescribing FDA-approved drugs for newly discovered uses. This unprecedented interference with the practice of medicine could result in thousands of needless deaths, and delay control of a deadly pandemic."

The Association of American Physicians and Surgeons (AAPS) has represented physicians of all specialties since 1943. Its motto is omnia pro aegroto?everything for the patient.

SOURCE Association of American Physicians and Surgeons (AAPS)


These press releases may also interest you

at 16:35
Atico Mining Corporation (the "Company" or "Atico") today announced its financial results for the year ended December 31, 2023, posting income from mining operations of $7.4 million and a net loss of $5.8 million. Production for the year at Atico's...

at 16:25
Precision BioSciences, Inc. , an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company. Precision exercised its option to regain...

at 16:25
AIDS Healthcare Foundation (AHF), the world's largest HIV/AIDS organization, is calling on public health officials to provide more education and prevention services around vaccinations as a new measles outbreak spreads through 17 U.S. states. As of...

at 16:25
CXApp Inc. , the global technology leader in employee workplace experiences announced record double digit Annual Recurring Revenue (ARR) growth in the fourth quarter of 2023 and 24% ARR growth for the full year 2023. This growth is tied to two large...

at 16:15
K92 Mining Inc. ("K92" or the "Company") announces that it will release its 2024 first quarter financial results before the North American trading markets open on Monday, May 13, 2024. Conference Call and Webcast to Present Results K92 will...

at 16:15
Phoenix Motor Inc. , a leading manufacturer of heavy-duty transit buses and electrification solutions provider for medium-duty vehicles, today announced it is hosting an Investor Day on April 18, 2024 at its recently acquired transit bus...



News published on and distributed by: